{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:47:49Z","timestamp":1782211669192,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03563-x","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:25:46Z","timestamp":1777965946000},"page":"2897-2912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T.","family":"Ritchlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2029","authenticated-orcid":false,"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"3563_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"3563_CR2","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","volume":"76","author":"A Kerschbaumer","year":"2017","unstructured":"Kerschbaumer A, Baker D, Smolen JS, Aletaha D. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. 2017;76:2038\u201345.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR3","first-page":"680","volume":"35","author":"S Lee","year":"2010","unstructured":"Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35:680\u20139.","journal-title":"P T"},{"key":"3563_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6\u00a0months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045\u201350.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/ar3049","volume":"12","author":"DD Gladman","year":"2010","unstructured":"Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010;12:R113.","journal-title":"Arthritis Res Ther"},{"key":"3563_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004080","volume":"10","author":"GH Koc","year":"2024","unstructured":"Koc GH, Kok MR, do Rosario Y, et al. Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort. RMD Open. 2024;10:e004080.","journal-title":"RMD Open"},{"key":"3563_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1399-5","volume":"19","author":"A Polachek","year":"2017","unstructured":"Polachek A, Cook R, Chandran V, Gladman DD, Eder L. The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. Arthritis Res Ther. 2017;19:189.","journal-title":"Arthritis Res Ther"},{"key":"3563_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2003.018184","volume":"64","author":"JE Brockbank","year":"2005","unstructured":"Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188\u201390.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"3563_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706\u201319.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/rheumatology\/key417","volume":"58","author":"R Landew\u00e9","year":"2019","unstructured":"Landew\u00e9 R, Ritchlin CT, Aletaha D, et al. Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. Rheumatol (Oxford). 2019;58:1025\u201333.","journal-title":"Rheumatol (Oxford)"},{"key":"3563_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2126-1","volume":"22","author":"P Mease","year":"2020","unstructured":"Mease P, Husni ME, Kafka S, et al. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. Arthritis Res Ther. 2020;22:43.","journal-title":"Arthritis Res Ther"},{"key":"3563_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/art.20982","volume":"52","author":"JS Smolen","year":"2005","unstructured":"Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020\u201330.","journal-title":"Arthritis Rheum"},{"key":"3563_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65:1213\u201323.","journal-title":"Arthritis Rheum"},{"key":"3563_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"JF Merola","year":"2017","unstructured":"Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47:29\u201337.","journal-title":"Semin Arthritis Rheum"},{"key":"3563_CR16","unstructured":"Otezla: Package insert. Thousand Oaks, CA: Amgen Inc.; 2025."},{"key":"3563_CR17","unstructured":"Xeljanz: Package insert. New York, NY: Pfizer; 2025."},{"key":"3563_CR18","unstructured":"Rinvoq: Package insert. North Chicago, IL: AbbVie; 2025."},{"key":"3563_CR19","unstructured":"Orencia: Package insert. Princeton, NJ: Bristol Myers Squibb; 2023."},{"key":"3563_CR20","unstructured":"Cosentyx: Package insert. East Hanover, NJ: Novartis; 2024."},{"key":"3563_CR21","unstructured":"Taltz: Package insert. Indianapolis, IN: Eli Lilly and Company; 2024."},{"key":"3563_CR22","unstructured":"Bimzelx: Package insert. Smyrna, GA: UCB, Inc; 2024."},{"key":"3563_CR23","unstructured":"Stelara: Package insert. Horsham, PA: Janssen Biotech, Inc.; 2024."},{"key":"3563_CR24","unstructured":"Tremfya: Package insert. Horsham, PA: Janssen Biotech, Inc.; 2025."},{"key":"3563_CR25","unstructured":"Skyrizi: Package insert. North Chicago, IL: AbbVie; 2025."},{"key":"3563_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl 2","key":"3563_CR27","doi-asserted-by":"publisher","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","volume":"64","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis. 2005;64(Suppl 2):ii61\u20134.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR28","doi-asserted-by":"crossref","unstructured":"Helliwell PS, Porter G, Taylor WJ, for the Caspar Study Group. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis. 2007;66:113\u20137.","DOI":"10.1136\/ard.2006.054288"},{"key":"3563_CR29","unstructured":"Tiwari V, Brent LH. Psoriatic arthritis. StatPearls. Treasure Island (FL); 2024."},{"key":"3563_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/rheumatology\/key297","volume":"58","author":"A Allard","year":"2019","unstructured":"Allard A, Antony A, Shaddick G, et al. Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis. Rheumatol (Oxford). 2019;58:269\u201373.","journal-title":"Rheumatol (Oxford)"},{"key":"3563_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.berh.2013.03.004","volume":"27","author":"AK Brown","year":"2013","unstructured":"Brown AK. How to interpret plain radiographs in clinical practice. Best Pract Res Clin Rheumatol. 2013;27:249\u201369.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3563_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00223-017-0380-2","volume":"102","author":"A Paine","year":"2018","unstructured":"Paine A, Ritchlin C. Altered bone remodeling in psoriatic disease: new insights and future directions. Calcif Tissue Int. 2018;102:559\u201374.","journal-title":"Calcif Tissue Int"},{"key":"3563_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-021-01035-0","volume":"12","author":"AM Crespo-Rodriguez","year":"2021","unstructured":"Crespo-Rodriguez AM, Sanz Sanz J, Freites D, Rosales Z, Abasolo L, Arrazola J. Role of diagnostic imaging in psoriatic arthritis: how, when, and why. Insights Imaging. 2021;12:121.","journal-title":"Insights Imaging"},{"key":"3563_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","volume":"48","author":"GS Kaeley","year":"2018","unstructured":"Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C. Enthesitis: a hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48:35\u201343.","journal-title":"Semin Arthritis Rheum"},{"key":"3563_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241288060","volume":"16","author":"Y Jin","year":"2024","unstructured":"Jin Y, Cheng IT, Wu D, et al. Imaging in psoriatic arthritis: established methods and emerging techniques. Ther Adv Musculoskelet Dis. 2024;16:1759720X241288060.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3563_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/000155598442809","volume":"78","author":"A Offidani","year":"1998","unstructured":"Offidani A, Cellini A, Valeri G, Giovagnoni A. Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Acta Derm Venereol. 1998;78:463\u20135.","journal-title":"Acta Derm Venereol"},{"key":"3563_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.804695","volume":"8","author":"T Gudu","year":"2022","unstructured":"Gudu T, Ng B, Jethwa H, et al. Improving imaging modalities in early psoriatic arthritis: the role of ultrasound in early diagnosis of psoriatic arthritis. Front Med. 2022;8:804695.","journal-title":"Front Med"},{"key":"3563_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2103-8","volume":"22","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020;22:18.","journal-title":"Arthritis Res Ther"},{"key":"3563_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.semarthrit.2021.01.008","volume":"51","author":"A Antony","year":"2021","unstructured":"Antony A, Holland R, D\u2019Agostino MA, et al. Measurement properties of radiographic outcome measures in psoriatic arthritis: a systematic review from the GRAPPA-OMERACT initiative. Semin Arthritis Rheum. 2021;51:367\u201386.","journal-title":"Semin Arthritis Rheum"},{"key":"3563_CR40","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/jdv.14868","volume":"32","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32:1111\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3563_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2040622318759282","volume":"9","author":"TC Chan","year":"2018","unstructured":"Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9:111\u20139.","journal-title":"Ther Adv Chronic Dis"},{"key":"3563_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103167","volume":"143","author":"H Furuya","year":"2024","unstructured":"Furuya H, Nguyen CT, Chan T, et al. IL-23 induces CLEC5A(+) IL-17A(+) neutrophils and elicit skin inflammation associated with psoriatic arthritis. J Autoimmun. 2024;143:103167.","journal-title":"J Autoimmun"},{"key":"3563_CR43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4049\/jimmunol.1003986","volume":"187","author":"IE Adamopoulos","year":"2011","unstructured":"Adamopoulos IE, Tessmer M, Chao CC, et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol. 2011;187:951\u20139.","journal-title":"J Immunol"},{"key":"3563_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65269-6","volume":"10","author":"L Chen","year":"2020","unstructured":"Chen L, Deshpande M, Grisotto M, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10:8259.","journal-title":"Sci Rep"},{"key":"3563_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/BOR.0000000000000232","volume":"28","author":"A Paine","year":"2016","unstructured":"Paine A, Ritchlin C. Bone remodeling in psoriasis and psoriatic arthritis: an update. Curr Opin Rheumatol. 2016;28:66\u201375.","journal-title":"Curr Opin Rheumatol"},{"key":"3563_CR46","doi-asserted-by":"publisher","first-page":"10928","DOI":"10.1038\/ncomms10928","volume":"7","author":"T Ono","year":"2016","unstructured":"Ono T, Okamoto K, Nakashima T, et al. IL-17-producing \u03b3\u03b4 T\u00a0cells enhance bone regeneration. Nat Commun. 2016;7:10928.","journal-title":"Nat Commun"},{"key":"3563_CR47","doi-asserted-by":"publisher","first-page":"1532852","DOI":"10.3389\/fimmu.2025.1532852","volume":"16","author":"KL Sachen","year":"2025","unstructured":"Sachen KL, Hammaker D, Sarabia I, et al. Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling. Front Immunol. 2025;16:1532852.","journal-title":"Front Immunol"},{"key":"3563_CR48","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395:1115\u201325.","journal-title":"Lancet"},{"key":"3563_CR49","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395:1126\u201336.","journal-title":"Lancet"},{"key":"3563_CR50","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"3563_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1\u00a0year results of a phase\u00a0III randomised study of patients who were biologic-naive or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7:e001457.","journal-title":"RMD Open"},{"key":"3563_CR52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase\u00a0III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475\u201385.","journal-title":"Arthritis Rheumatol"},{"key":"3563_CR53","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s10067-024-06991-8","volume":"43","author":"CT Ritchlin","year":"2024","unstructured":"Ritchlin CT, Mease PJ, Boehncke WH, et al. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase\u00a03 study. Clin Rheumatol. 2024;43:2551\u201363.","journal-title":"Clin Rheumatol"},{"key":"3563_CR54","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-na\u00efve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73:604\u201316.","journal-title":"Arthritis Rheumatol"},{"key":"3563_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002789","volume":"9","author":"AB Gottlieb","year":"2023","unstructured":"Gottlieb AB, McInnes IB, Rahman P, et al. Low rates of radiographic progression associated with clinical efficacy following up to 2\u00a0years of treatment with guselkumab: results from a phase\u00a03, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis. RMD Open. 2023;9:e002789.","journal-title":"RMD Open"},{"key":"3563_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10067-023-06745-y","volume":"43","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Gottlieb AB, Ogdie A, et al. Earlier clinical response predicts low rates of radiographic progression in biologic-naive patients with active psoriatic arthritis receiving guselkumab treatment. Clin Rheumatol. 2024;43:241\u20139.","journal-title":"Clin Rheumatol"},{"key":"3563_CR57","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/art.40527","volume":"70","author":"CF Kjelgaard-Petersen","year":"2018","unstructured":"Kjelgaard-Petersen CF, Platt A, Braddock M, et al. Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis. Arthritis Rheumatol. 2018;70:1419\u201328.","journal-title":"Arthritis Rheumatol"},{"key":"3563_CR58","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00296-011-2237-8","volume":"32","author":"AC Bay-Jensen","year":"2012","unstructured":"Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int. 2012;32:3565\u201372.","journal-title":"Rheumatol Int"},{"key":"3563_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207324","volume":"13","author":"P Juhl","year":"2018","unstructured":"Juhl P, Bay-Jensen AC, Karsdal M, Siebuhr AS, Franchimont N, Chavez J. Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: a cross-sectional study. PLoS One. 2018;13:e0207324.","journal-title":"PLoS One"},{"key":"3563_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-03804-2","volume":"21","author":"CS Thudium","year":"2020","unstructured":"Thudium CS, Nielsen SH, Sardar S, et al. Bone phenotypes in rheumatology - there is more to bone than just bone. BMC Musculoskelet Disord. 2020;21:789.","journal-title":"BMC Musculoskelet Disord"},{"key":"3563_CR61","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40744-022-00444-x","volume":"9","author":"G Schett","year":"2022","unstructured":"Schett G, Loza MJ, Palanichamy A, et al. Collagen turnover biomarkers associate with active psoriatic arthritis and decrease with guselkumab treatment in a phase\u00a03 clinical trial (DISCOVER-2). Rheumatol Ther. 2022;9:1017\u201330.","journal-title":"Rheumatol Ther"},{"key":"3563_CR62","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241283536","volume":"16","author":"S Siebert","year":"2024","unstructured":"Siebert S, Schett G, Raychaudhuri SP, et al. Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2\u00a0years in participants with active psoriatic arthritis: results from a phase\u00a0III randomized controlled trial. Ther Adv Musculoskelet Dis. 2024;16:1759720X241283536.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3563_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06945-y","volume":"24","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Coates LC, Mease PJ, et al. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase\u00a03b, multicenter, randomized, double-blind, placebo-controlled trial. Trials. 2023;24:22.","journal-title":"Trials"},{"key":"3563_CR64","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.ard.2025.08.006","volume":"84","author":"PJ Mease","year":"2025","unstructured":"Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week\u00a024 of the phase\u00a03b, randomised, double-blind, placebo-controlled APEX study. Ann Rheum Dis. 2025;84:1983\u201394.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase\u00a03 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81:225\u201331.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR66","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase\u00a0III FUTURE\u00a05 study. Ann Rheum Dis. 2018;77:890\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase\u00a0III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79\u201387.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase\u00a03 trial (BE OPTIMAL). Lancet. 2023;401:25\u201337.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"3563_CR69","doi-asserted-by":"publisher","first-page":"ii46","DOI":"10.1136\/ard.2004.030817","volume":"64","author":"A Kavanaugh","year":"2005","unstructured":"Kavanaugh A. Ethical and practical issues in conducting clinical trials in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 2):ii46\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3563_CR70","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2023-2-2","volume":"12","author":"TC Hardman","year":"2023","unstructured":"Hardman TC, Aitchison R, Scaife R, Edwards J, Slater G. The future of clinical trials and drug development: 2050. Drugs Context. 2023;12:2023-2-2.","journal-title":"Drugs Context"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03563-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03563-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03563-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:03:40Z","timestamp":1782209020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03563-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3563"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03563-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are members of the APEX Steering Committee. Christopher T Ritchlin received grant\/research support from AbbVie, Amgen, and UCB and consulting fees from AbbVie, Amgen, Eli Lilly, Gilead, Johnson & Johnson, Novartis, Pfizer, and UCB. Laura C Coates received grant\/research support from AbbVie, Amgen, Celgene, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB; consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Johnson & Johnson, Moonlake, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Pfizer, and UCB. Dr. Coates is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Philip J Mease received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Century, Cullinan, Eli Lilly, Inmagene, Johnson & Johnson, Merck, Moonlake, Novartis, Pfizer, Spyre, SUN Pharma, Takeda, and UCB; grants from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, Sana, and UCB; and speaker fees from AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and UCB. D\u00e9sir\u00e9e van der Heijde received consulting fees from AbbVie, Alfasigma, ArgenX, Bristol Myers Squibb, Eli Lilly, Grey-Wolf Therapeutics, Johnson & Johnson, Novartis, Pfizer, Takeda, and UCB and is associate editor of\n                      Annals Rheumatic Diseases\n                      , editorial board member\n                      Journal of Rheumatology\n                      , and director of Imaging Rheumatology BV. Proton Rahman received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and UCB; meeting attendance\/travel support from Johnson & Johnson; and research grants from Johnson & Johnson and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}